Literature DB >> 20826165

Identification of an allosteric signaling network within Tec family kinases.

Raji E Joseph1, Qian Xie, Amy H Andreotti.   

Abstract

The Tec family kinases are tyrosine kinases that function primarily in hematopoietic cells. The catalytic activity of the Tec kinases is positively influenced by the regulatory domains outside of the kinase domain. The current lack of a full-length Tec kinase structure leaves a void in our understanding of how these positive regulatory signals are transmitted to the kinase domain. Recently, a conserved structure within kinases, the 'regulatory spine', which assembles and disassembles as a kinase switches between its active and inactive states, has been identified. Here, we define the residues that comprise the regulatory spine within Tec kinases. Compared to previously characterized systems, the Tec kinases contain an extended regulatory spine that includes a conserved methionine within the C-helix and a conserved tryptophan within the Src homology 2-kinase linker of Tec kinases. This extended regulatory spine forms a conduit for transmitting the presence of the regulatory domains of Tec kinases to the catalytic domain. We further show that mutation of the gatekeeper residue at the edge of the regulatory spine stabilizes the regulatory spine, resulting in a constitutively active kinase domain. Importantly, the regulatory spine is preassembled in this gatekeeper mutant, rendering phosphorylation on the activation loop unnecessary for its activity. Moreover, we show that the disruption of the conserved electrostatic interaction between Bruton's tyrosine kinase R544 on the activation loop and Bruton's tyrosine kinase E445 on the C-helix also aids in the assembly of the regulatory spine. Thus, the extended regulatory spine is a key structure that is critical for maintaining the activity of Tec kinases.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826165      PMCID: PMC2949508          DOI: 10.1016/j.jmb.2010.08.035

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  33 in total

1.  Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.

Authors:  C Mao; M Zhou; F M Uckun
Journal:  J Biol Chem       Date:  2001-08-29       Impact factor: 5.157

Review 2.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

3.  Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.

Authors:  Kieron Brown; Joanna M Long; Sarah C M Vial; Neesha Dedi; Nicholas J Dunster; Suzanne B Renwick; Adam J Tanner; J Dan Frantz; Mark A Fleming; Graham M T Cheetham
Journal:  J Biol Chem       Date:  2004-02-06       Impact factor: 5.157

Review 4.  Structure and regulation of Src family kinases.

Authors:  Titus J Boggon; Michael J Eck
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

5.  Regulation of the enzymatic function of the lymphocyte-specific tyrosine protein kinase p56lck by the non-catalytic SH2 and SH3 domains.

Authors:  A Veillette; L Caron; M Fournel; T Pawson
Journal:  Oncogene       Date:  1992-05       Impact factor: 9.867

6.  Structure of the carboxyl-terminal Src kinase, Csk.

Authors:  Akira Ogawa; Yoshiharu Takayama; Hiroaki Sakai; Khoon Tee Chong; Satoru Takeuchi; Atsushi Nakagawa; Shigeyuki Nada; Masato Okada; Tomitake Tsukihara
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

Review 7.  Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).

Authors:  M Vihinen; P T Mattsson; C I Smith
Journal:  Front Biosci       Date:  2000-12-01

8.  Itk phosphorylation sites are required for functional activity in primary T cells.

Authors:  Heather M Wilcox; Leslie J Berg
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

9.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.

Authors:  Douglas J Marcotte; Yu-Ting Liu; Robert M Arduini; Catherine A Hession; Konrad Miatkowski; Craig P Wildes; Patrick F Cullen; Victor Hong; Brian T Hopkins; Elisabeth Mertsching; Tracy J Jenkins; Michael J Romanowski; Darren P Baker; Laura F Silvian
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

10.  Regulation of Btk function by a major autophosphorylation site within the SH3 domain.

Authors:  H Park; M I Wahl; D E Afar; C W Turck; D J Rawlings; C Tam; A M Scharenberg; J P Kinet; O N Witte
Journal:  Immunity       Date:  1996-05       Impact factor: 31.745

View more
  22 in total

1.  Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Authors:  Shenqiu Wang; Sayan Mondal; Chunying Zhao; Marjan Berishaj; Phani Ghanakota; Connie Lee Batlevi; Ahmet Dogan; Venkatraman E Seshan; Robert Abel; Michael R Green; Anas Younes; Hans-Guido Wendel
Journal:  JCI Insight       Date:  2019-06-20

2.  Bruton's tyrosine kinase mediates FcγRIIa/Toll-like receptor-4 receptor crosstalk in human neutrophils.

Authors:  Agnieszka Krupa; Rafal Fudala; Jon M Florence; Torry Tucker; Timothy C Allen; Theodore J Standiford; Rafal Luchowski; Marek Fol; Moshiur Rahman; Zygmunt Gryczynski; Ignacy Gryczynski; Anna K Kurdowska
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-13       Impact factor: 6.914

Review 3.  Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.

Authors:  Peter Csermely; Tamás Korcsmáros; Huba J M Kiss; Gábor London; Ruth Nussinov
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

4.  Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.

Authors:  Wenchang Guo; Ruiwu Liu; Yoko Ono; Ai-Hong Ma; Anthony Martinez; Eduardo Sanchez; Yan Wang; Wenzhe Huang; Anisha Mazloom; Jixian Li; Jinying Ning; Emanual Maverakis; Kit S Lam; Hsing-Jien Kung
Journal:  Mol Pharmacol       Date:  2012-08-16       Impact factor: 4.436

5.  Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Biochemistry       Date:  2010-12-16       Impact factor: 3.162

6.  Rescue of the aggregation prone Itk Pleckstrin Homology domain by two mutations derived from the related kinases, Btk and Tec.

Authors:  Scott E Boyken; D Bruce Fulton; Amy H Andreotti
Journal:  Protein Sci       Date:  2012-07-16       Impact factor: 6.725

7.  Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts.

Authors:  Raji E Joseph; Thomas E Wales; D Bruce Fulton; John R Engen; Amy H Andreotti
Journal:  Structure       Date:  2017-08-31       Impact factor: 5.006

8.  Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.

Authors:  Raji E Joseph; Iivari Kleino; Thomas E Wales; Qian Xie; D Bruce Fulton; John R Engen; Leslie J Berg; Amy H Andreotti
Journal:  Sci Signal       Date:  2013-08-27       Impact factor: 8.192

9.  A conserved isoleucine maintains the inactive state of Bruton's tyrosine kinase.

Authors:  Scott E Boyken; Nikita Chopra; Qian Xie; Raji E Joseph; Thomas E Wales; D Bruce Fulton; John R Engen; Robert L Jernigan; Amy H Andreotti
Journal:  J Mol Biol       Date:  2014-09-02       Impact factor: 5.469

10.  BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

Authors:  H Yesid Estupiñán; Qing Wang; Anna Berglöf; Gerard C P Schaafsma; Yuye Shi; Litao Zhou; Dara K Mohammad; Liang Yu; Mauno Vihinen; Rula Zain; C I Edvard Smith
Journal:  Leukemia       Date:  2021-02-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.